Pfizer, Lundbeckfonden Ventures and Biomed Ventures have all taken part in a round for the anti-infective therapy developer that has now passed $90m.

US-based anti-infective drug developer Amplyx Pharmaceuticals increased its series C round to more than $90m on Tuesday with extra funding from investors including pharmaceutical firms Pfizer and Lundbeck. The company announced in 2017 that it had raised $67m in series C funding, but a securities filing at the time indicates only $40m had been closed.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.